All In Biotech

Drug Trial Radar · NCT02946073

Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Enriched-Enrollment Withdrawal, Multicenter Study to Evaluate the Efficacy and Safety of a Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Subjects With Moderate to Severe Chronic Low Back Pain Currently Treated With Daily Opioids

Last checked: Nov 19, 2026Latest source record: Oct 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,053 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,053

Actual

Start

Sep 2016

Primary completion

May 2018

Study completion Feb 2019

Sponsor

Lead sponsor
Braeburn PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Medpace, Inc.; Camurus AB
First posted
Oct 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, placebo-controlled, multicenter study with an enriched-enrollment withdrawal (EEW) design to evaluate the efficacy and safety of CAM2038 in opioid-experienced subjects with moderate to severe CLBP that requires continuous, around-the-clock (ATC) opioid treatment ≥ 40 mg morphine equivalent dose (MED). The study includes 5 phases: A Screening Phase (up to 2 weeks), a Transition Phase (up to 2 weeks), an Open-Label Titration Phase (up to 10 weeks), a Double-Blind Treatment Phase including a Final Study Visit (12 weeks), and a Follow-up Phase (4 weeks). The overall duration of participation in the core phase of the study (randomized Double-Blind Phase) is up to 30 weeks, from the Screening Phase through the Follow-up Phase. Subjects who complete the Double-Blind Treatment Study Phase will be offered an opportunity to continue treatment in an open label safety extension for up to 60 weeks. Additional subjects may be recruited to open label safety extension to meet the goal of 100 subjects with 60 weeks of treatment.

Conditions

  • Chronic Lower Back Pain
  • Chronic Pain

Interventions

  • buprenorphineDrug

  • PlaceboOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) and the Primary Timepoint Will be Week 12 of the Double-Blind Phase.Time frame: 12 weeks- from randomization baseline to 12 weeks after randomization
  2. Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) of the Open Label Phase.Time frame: 48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).

Locations

69 sites in 1 country. Site status is shown where the registry gives one.

  • Parkway Medical Center

    Birmingham, Alabama

  • Boyett Health Services Inc

    Hamilton, Alabama

  • National Centers for Pain Management and Research

    Vestavia Hills, Alabama

  • Elite Clinical Studies

    Phoenix, Arizona

  • Phoenix Clinical

    Phoenix, Arizona

  • Noesis Pharma

    Phoenix, Arizona

  • Arizona Research Center

    Phoenix, Arizona

  • MD Studies, Inc.

    Fountain Valley, California

  • Neuro-Pain Medical Center

    Fresno, California

  • Alliance Research Centers

    Laguna Hills, California

  • Clinical Trials Research

    Lincoln, California

  • Catalina Research Institute, LLC

    Montclair, California

  • Allied Clinical Research, LLC

    Sacramento, California

  • Care Practice

    San Francisco, California

  • Syrentis Clinical Research

    Santa Ana, California

  • Universal Pain Management Group

    Valencia, California

  • Tampa Pain Relief Center-Brandon

    Brandon, Florida

  • International Research Partners

    Doral, Florida

  • Dr. Vijapura and Associates

    Jacksonville, Florida

  • Florida Institute of Medical Research

    Jacksonville, Florida

  • Lake Howell Health Center

    Maitland, Florida

  • Ocean Blue Medical Research Center, Inc.

    Miami Springs, Florida

  • Scientific Clinical Research, Inc.

    North Miami, Florida

  • Gold Coast Research, LLC

    Plantation, Florida

  • FMPM Research

    St. Petersburg, Florida

  • Clinical Research of West Florida-Tampa

    Tampa, Florida

  • Tampa Pain Relief Centers-Hillsborough

    Tampa, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • River Birch Research Alliance LLC

    Blue Ridge, Georgia

  • Columbus Regional Research Institute

    Knoxville, Georgia

  • Drug Studies America

    Marietta, Georgia

  • Non-Surgical Orthopedics, P.C.

    Marietta, Georgia

  • Injury Care Research, LLC

    Boise, Idaho

  • Millennium Pain Center

    Bloomington, Illinois

  • Clinical Investigation Specialists, Inc.-Gurnee

    Gurnee, Illinois

  • Medisphere Medical Research Center

    Evansville, Indiana

  • International Clinical Research Institute Inc.

    Overland Park, Kansas

  • Phoenix Medical Research

    Prairie Village, Kansas

  • Otrimed

    Edgewood, Kentucky

  • River Cities Clinical Research Center

    Shreveport, Louisiana

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.